Characterization of SPR994, an Orally Available Carbapenem, with Activity Comparable to Intravenously Administered Carbapenems Posted on August 17, 2018 at 2:47 pm.Written by Spero Therapeutics ACS Infect. Dis., DOI: 10.1021/acsinfecdis.8b00188 Aileen Rubio, Michael J. Pucci, and Akash Jain View Presentation Post navigation Tebipenem, the First Oral Carbapenem AntibioticPatient Demographics And Comorbidity Profiles Associated With Hospitalized Patients Admitted With Resistant Versus Susceptible Urinary Tract Infections (UTI): A Multicenter Analysis
